Nutrition plays a major role in cancer development and treatment. Malnutrition is a significant and common problem in cancer patients and has been recognized as an important component of adverse outcomes, including increased morbidity and mortality. At the time of diagnosis, the majority of patients with upper gastrointestinal cancer, including those having undergone gastrectomy, have already suffered from significant nutritional deficiencies. Therefore, optimization of nutritional status can help cancer patients maintain the body's nutrition stores and improve symptoms such as anemia and neuropathy that may be associated with nutritional deficiencies. Depending on the etiology of symptoms, iron or Vitamin B12 (injection or oral) may be given. Early recognition and detection of risk for malnutrition may be performed using nutrition screening followed by comprehensive assessments. The most effective approach to malnutrition and nutritional deficiency is the prevention of its initiation through nutrition monitoring and intervention.
Anemia ; Gastrectomy ; Gastrointestinal Neoplasms ; Humans ; Iron ; Malnutrition ; Mass Screening ; Nutritional Status ; Postgastrectomy Syndromes ; Vitamin B 12

Despite the rarity in incidence and prevalence, gastrointestinal stromal tumor (GIST) has emerged as a distinct pathogenetic entity. And the clinical management of GIST has been evolving very rapidly due to the recent recognition of its oncogenic signal transduction pathway and the introduction of new molecular-targeted therapy. Successful management of GIST requires a multidisciplinary approach firmly based on accurate histopathologic diagnosis. However, there was no standardized guideline for the management of Korean GIST patients. In 2007, the Korean GIST study group (KGSG) published the first guideline for optimal diagnosis and treatment of GIST in Korea. As the second version of the guideline, we herein have updated recent clinical recommendations and reflected changes in diagnosis, surgical and medical treatments for more optimal clinical practice for GIST in Korea. We hope the guideline can be of help in enhancing the quality of diagnosis by members of the Korean associate of physicians involving in GIST patients's care and subsequently in achieving optimal efficacy of treatment.
Antineoplastic Agents/therapeutic use ; Gastrointestinal Stromal Tumors/*pathology/surgery/*therapy ; Humans ; Neoadjuvant Therapy ; Piperazines/therapeutic use ; Proto-Oncogene Proteins c-kit/metabolism ; Pyrimidines/therapeutic use ; Recurrence ; Republic of Korea ; Tumor Markers, Biological/metabolism

Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.
Benzamides ; Gastrointestinal Stromal Tumors ; Incidence ; Indoles ; Korea ; Molecular Targeted Therapy ; Patient Care ; Piperazines ; Prevalence ; Pyrimidines ; Pyrroles ; Signal Transduction ; Imatinib Mesylate

BACKGROUND/AIMS: Colorectal cancer incidence among patients aged ≤50 years is increasing. This study aimed to develop and validate an advanced colorectal neoplasm (ACRN) screening model for young adults aged <50 years in Korea. METHODS: This retrospective cross-sectional study included 59,575 consecutive asymptomatic Koreans who underwent screening colonoscopy between 2003 and 2012 at a single comprehensive health care center. Young Adult Colorectal Screening (YCS) score was developed as an optimized risk stratification model for ACRN using multivariate analysis and was internally validated. The predictive power and diagnostic performance of YCS score was compared with those of Asia-Pacific Colorectal Screening (APCS) and Korean Colorectal Screening (KCS) scores. RESULTS: 41,702 and 17,873 subjects were randomly allocated into the derivation and validation cohorts, respectively, by examination year. ACRN prevalence was 0.9% in both cohorts. YCS score comprised sex, age, alcohol, smoking, obesity, glucose metabolism abnormality, and family history of CRC, with score ranges of 0 to 10. In the validation cohort, ACRN prevalence was 0.6% in the low-risk tier (score, 0–4), 1.5% in the moderate-risk tier (score, 5–7), and 3.4% in the high-risk tier (score, 8–10). ACRN risk increased 2.5-fold (95% confidence interval [CI], 1.8–3.4) in the moderate-risk tier and 5.8-fold (95% CI, 3.4–9.8) in the high-risk tier compared with the low-risk tier. YCS score identified better balanced accuracy (53.9%) than APCS (51.5%) and KCS (50.7%) scores and had relatively good discriminative power (area under the curve=0.660). CONCLUSIONS: YCS score based on clinical and laboratory risk factors was clinically effective and beneficial for predicting ACRN risk and targeting screening colonoscopy in adults aged <50 years.
Adult ; Cohort Studies ; Colonoscopy ; Colorectal Neoplasms ; Comprehensive Health Care ; Cross-Sectional Studies ; Early Detection of Cancer ; Glucose ; Humans ; Incidence ; Korea ; Mass Screening ; Metabolism ; Multivariate Analysis ; Obesity ; Prevalence ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Smoke ; Smoking ; Young Adult